The primary clinical endpoint is an increase in the distance walked in six minutes...MGI Pharma Inc., of Minneapolis, said the March edition of The European Journal of Neurosurgery, Acta Neurochirurgica, published 56-month follow-up data showing that Gliadel Wafer provided a durable long-term survival benefit for patients with high-grade malignant glioma...Santarus Inc., of San Diego, said clinical results indicated Zegerid (omeprazole/sodium bicarbonate) powder for oral suspension provided physicians

Clinical testing with NPI-2358 will begin in solid tumors...We have two lead clinical compounds, backup compounds and others in the pipeline that could be developed if we so desire...Antares Pharma Inc., of Exton, Pa., completed its previously announced financing of nearly $11 million through a private placement of units consisting of 8.8 million shares of stock priced at $1.25 each, plus warrants to purchase 6.6 million shares at an exercise price of $1.50 per share

Its lead candidate, cethromycin, is a ketolide antibiotic in late-stage clinical development for respiratory tract infections...The clinical cure rate at the test-of-cure visit is the primary endpoint of the trial, which is powered to demonstrate non-inferiority at the 95 percent confidence interval...In separate news, Cytomics appointed John Thebault to the position of director of clinical research

According to the company's prospectus, Theravance intends to spend the proceeds on general corporate purposes, which might include funding clinical and preclinical development candidates, drug research activities, manufacturing of drug supplies, capital expenditures and working capital...Proceeds will be used for the clinical development of its three lead preclinical candidates, including its lead drug Alchemix, a multi-target inhibitor that overcomes chemotherapeutic drug resistance by binding to

The company acquired worldwide rights to XY 2405 from Paris-based Fournier Pharma last year...Hawaii Biotech Inc., of Honolulu, raised $7.8 million in its Series C financing, with proceeds expected to go toward its anti-inflammatory small-molecule programs, including the preclinical and early clinical development of Cardax, a potential treatment for cardiovascular inflammatory disease...private equity fund, WFD Ventures LLC, with undisclosed proceeds expected to support its clinical development

A third clinical-stage product, pleconaril, aimed at treating the common cold and asthma exacerbations is no longer considered part of ViroPharma's pipeline...Gastrotech Completes €2.3M Round Danish firm Gastrotech Pharma A/S raised €2.3 million (US$2.7 million) in a private equity financing...Its clinical programs include GTP-010 for irritable bowel syndrome and GTP-200 for the treatment of cachexia and other catabolic syndromes

is bringing in $18 million through a public offering to support clinical development...But the company has yet to disclose a timeline for the clinical development of its avian flu product, which so far had been tested only in preclinical models, and from there, questions of the product's efficacy and production efficiency will come into play...Raphael Wisniewski, of Edmond de Rothschild, joined the company's board.

Staff Writer With its three lead products expected to be in clinical trials next year, Surface Logix Inc...Scolr Pharma Inc., of Bellevue, Wash., filed a shelf registration statement to sell up to $40 million in common stock and/or common stock purchase warrants...Kathy LaPorte, managing director of New Leaf Venture Partners, joined the company's board.

All of the shares are outstanding, and most were sold by Endo's largest shareholder, Endo Pharma LLC, which now holds about 17 percent of Endo's outstanding common stock...The company said it expects to use proceeds to fund clinical development and other research and development activities, as well as for working capital and general corporate purposes...Proceeds from the offering are expected to be used for clinical development of TH-070 in symptomatic benign prostatic hyperplasia, glucosfamide for

According to its prospectus, net proceeds of about $81.1 million will go toward clinical trials, research and development, general corporate purposes, capital expenditures, acquisitions of new technologies and working capital...Certain members of Endo's management have an ownership interest in Endo Pharma, and certain executive stockholders and directors of Endo also will receive proceeds through the transaction...Over the last few years, Kelso & Co., looking for liquidity, has reduced Endo Pharma's

priced its initial public offering, raising $42 million to fund upcoming clinical trials of its top three cell-cycle inhibitors in development for cancer...Clinical trials of SNS-314 are expected to begin next year...Following the completion of the offering, Endo Pharma LLC will hold 20.5 percent of Endo's outstanding common stock

It also offers WAVE-based biomarker discovery and validation services in support of translational research, preclinical and clinical studies...We see a lot of upside in that business," he added, "not only from a pharma perspective but also from a diagnostics perspective...Piper Jaffray & Co., of Minneapolis, is acting as the offering's sole manager.

And the company intends to conduct some higher-dose, shorter-course clinical trials in adults...Faropenem was in-licensed in early 2004 from Daiichi Suntory Pharma, of Tokyo...Proceeds will be used to conduct clinical testing of the company's GP88 Biopsy Staining Kit for breast cancer

Nutra Pharma was formed in 2001 to acquire and license drugs and technologies for treating neurological disorders, cancer and autoimmune and infectious diseases...Prior to this financing arrangement, Nutra Pharma had raised about $4 million and had about 67 million shares outstanding...At that time, Nutra Pharma had about $18,377 in cash

The financing follows a $20 million initial license payment made to Anadys by Novartis Pharma AG, of Basel, Switzerland, in a deal signed in June to advance ANA975 and other Toll-like receptor 7 oral prodrugs for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV...Another Anadys clinical product, ANA380, is a Phase II hepatitis B virus compound that is co-developed with LG Life Sciences Ltd., of Seoul, South Korea...According to the company's prospectus, it will use the money for research and

The remaining net proceeds will go toward business operations, which could include preclinical and clinical trials, research and development, regulatory filings and product commercialization costs...Santaris Pharma A/S, of Copenhagen, Denmark, said it received additional financing of €4.4 million (US$5.3 million), part of the company's second private financing that is expected to raise a total of €20 million and close in the second half of the year...and Dansk Erhvervsinvestering, also of Copenhagen

Now the government realizes that big pharma has not come to the table," Cook told BioWorld Today, adding that "even for the little guys like us," there needs to be additional incentives and safeguards to entice further research...So the BioShield II bill includes tax breaks, intellectual property protections such as patent incentives that could help spur countermeasures, as well as liability protections to companies who produce vaccines that cannot be fully tested in clinical trials because of the

is raising $28 million in a public offering to fund ongoing development activities, including preclinical and clinical evaluation of its two lead protein products...Its stock took a 22 percent plunge earlier this month, after the company reported the FDA's concerns regarding Laureate Pharma Inc., of Totowa, N.J., which manufactures Surfaxin, a synthetic compound containing the peptide sinapultide designed to mimic natural surfactant and allow oxygen absorption...30, the company had about $23 million

Human clinical evaluations of a CDT-based immediate-release Raloxifene formulation are set to begin next quarter...A portion also may be used to pay for the proposed acquisitions of ESP Pharma Inc...Last month, PDL announced it would buy the cardiovascular pharmaceutical firm ESP Pharma for $300 million in cash and $175 million in stock, in a deal that would yield PDL five marketed products and $14 million in ESP debt